OMEGA-3 & OLANZAPINE AUGMENTATION IMPLICATIONS TO COMBAT THE SCHIZOPHRENIA SYNDROMES; A CASE STUDY AT NISHTAR MEDICAL UNIVERSITY MULTAN.
Main Article Content
Keywords
Schizophrenia, Olanzapine, Ω-3fatty acids, Cognitive symptoms, Antipsychotic Drugs, PANSS Scale, Olanzapine + Ω-3 fatty acid.
Abstract
Schizophrenia is the leading cause of disability worldwide and individuals have significantly lower life expectancy, higher rates of suicide and higher prevalence of chronic health conditions when compared to the general population. Regarding treatment strategies along with rehabilitation services, many patients responded well to antipsychotic drugs. This study was conducted to investigate the Omega-3 Fatty Acids along with Olanzapine Augmentation potential benefits. A randomized controlled study design was adapted as inclusive criteria for schizophrenia patients with adjusted Olanzapine doses. The sample size was (N=45) including 30 schizophrenia patients while 15 individuals were healthy but prone to stress and this treatment lasts for six months with regular follow up. Olanzapine treatment was given to 15 out of 30 individuals while rest of the patients was treated with Olanzapine along with Omega-3(Ω-3) fatty acids. The stress prone individuals were also treated with Ω-3 fatty acid therapy. Positive and Negative Syndrome (PANSS) scale was used as assessment tool. The follow up interval was Four weeks up to six months for each group and results indicated that the group with adjusted Olanzapine doses didn’t express any deterioration in Schizophrenia symptoms and remain static, while the group with Olanzapine + Ω-3 fatty acid therapy exhibited significant improvements in all Schizophrenia symptoms. The 3rd/ Control group individuals with stress indicated satisfactory response by improvement in overall symptoms as positive and negative symptoms were taken to be absent in them. PANSS total scores of Olanzapine & Olanzapine + Ω-3 fatty acid therapy were compared. PANSS test scores for Olanzapine + Ω-3 fatty acid therapy indicated the significant improvement in Schizophrenia symptoms. Our findings provide the evidence for the potential therapeutic effects of Ω-3 fatty acid as an adjunct treatment to olanzapine in Schizophrenia symptoms management. However, this is one of the Preliminary study on Schizophrenia symptoms management, further studies are suggested for better insight
References
2. Fatouros-Bergman H, Cervenka S, Flyckt L. Meta-analysis of cognitive performance in drug-naive patients with schizophrenia. Schizophr Res. 2014; 158:156–62. https://doi.org /10.1016/ j. schres.2014.06.034.
3. Tsuang M. (2000) Schizophrenia: genes and environment. Biol. Psychiatr. 2000; 47:210–20. https://doi.org/10.1016/S0006-3223(99)00289-9.
4. Freedman R, Leonard S, Olincy A, Kaufmann CA, Malaspina D, Cloninger CR, et al. Evidence for the multigenic inheritance of schizophrenia. Am J Med Genet. 2001;105(8):794–800. https://doi.org/10.1002/ajmg.10100.
5. Hamazaki K, Maekawa M, Toyota T, Dean B, Hamazaki T, Yoshikawa T. Fatty acid composition of the postmortem corpus callosum of patients with schizophrenia, bipolar disorder, or major depressive disorder. Eur Psychiatry. 2017; 39:51–6. https://doi.org/10.1016/j. eurpsy. 2016.05.007
6. van Erp TG, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA, et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry. 2016;21(4):547–53. https://doi.org/ 10. 1038/mp.2015.63.
7. Mechelli A, Riecher-Rössler A, Meisenzahl EM, Tognin S, Wood SJ, Borgwardt SJ, et al. Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch Gen Psychiatry. 2011;68(5):489–95. https://doi.org/10.1001/archgenpsychiatry.2011.42.
8. Chan RCK, Di X, McAlonan GM, Gong QY. Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophr Bull. 2011;37(1):177–88. https:// doi.org/10.1093 / schbul/sbp073.
9. Ziermans TB, Schothorst PF, Schnack HG, Koolschijn PCMP, Kahn RS, van Engeland H, et al. Progressive structural brain changes during development of psychosis. Schizophr Bull. 2012;38(3):519–30. https://doi.org/10.1093/schbul/sbq113.
10. De Peri L, Crescini A, Deste G, Fusar-Poli P, Sacchetti E, Vita A. Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: A metaanalysis of controlled magnetic resonance imaging studies. Curr Pharmaceut Design. 2012; 18:486–94. https://doi.org/10.2174/138161212799316253.
11. Nenadic I, Dietzek M, Schönfeld N, Lorenz C, Gussew A, Reichenbach JR,et al. Brain structure in people at ultra-high risk of psychosis, patients with first-episode schizophrenia, and healthy controls: a VBM study. Schizophr Res. 2015;161(2-3):169–76. https://doi.org/10.1016/ j. schres.2014.10.041.
12. de Wit S, Wierenga LM, Oranje B, Ziermans TB, Schothorst PF, van Engeland H, et al. Brain development in adolescents at ultra-high risk for psychosis: Longitudinal changes related to resilience. NeuroImage Clin. 2016; 12:542–9. https://doi.org/10.1016/j.nicl.2016.08.013.
13. Gourion D, Gourevitch R, Leprovost JB, Olié H, Lôo JP, Krebs MO.Neurodevelopmental hypothesis in schizophrenia. Encephale. 2004; 30:109–18 French.
14. Denis I, Potier B, Heberden C, Vancassel S. Omega-3 polyunsaturated fatty acids and brain aging. Curr Opi. Clin Nut. Metab Care. 2015;18(2):139–46. https://doi.org/10.1097/ MCO.0000 000000000141.
15. Su HM. Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance. J Nutr Biochem. 2010;21(5):364–73. https://doi.org/10.1016/j.jnutbio. 2009.11.003.
16. Guesnet P, Alessandri JM. Docosahexaenoic acid (DHA) and the developing central nervous system (CNS) – implications for dietary recommendations. Biochimie. 2011;93(1):7–12. https:// doi.org/10.1016/j.biochi.2010.05.005.
17. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res. 1998; 30:193–208. https://doi.org/10.1016/S0920-9964(97)00151-5.
18. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res. 2000; 42:7– 17. https://doi.org/10.1016/S0920-9964(99)00095-X.
19. Assies J, Lieverse R, Vreken P, Wanders RJ, Dingemans PM, Linszen DH. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry. 2001;49(6):510–22. https://doi.org/10.1016/S0006-3223(00)00986-0.
20. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res. 2002; 58:1–10. https://doi.org/10.1016/S0920-9964(01)00334-6.
21. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res. 2003;62(3):195–204. https://doi.org/10.1016/s0920-9964(02)00284-0.
22. Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids. 2003; 69:393–9. https://doi.org/1 0.1016/j.plefa.2003.08.010.
23. Peet M, Shah S, Selvam K, Ramchand CN. Polyunsaturated fatty acid levels in red cell membranes of unmedicated schizophrenic patients. World J Biol Psychiatry. 2004;5(2):92–9. https://doi.org/10.1080/15622970410029917.
24. Reddy RD, Keshavan MS, Yao JK. Reduced red blood cell membrane essential poly unsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull. 2004;30(4):901–11. https://doi.org/10.1093/oxfordjournals.schbul.a007140.
25. Kale A, Joshi S, Naphade N, Sapkale S, Raju MS, Pillai A, et al. Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients. Schizophr Res. 2008;98(1-3):295–301. https://doi.org/10.1016/j.schres.2007.09.036.
26. Bentsen H, Solberg DK, Refsum H, Gran JM, Bohmer T, Torjesen PA, et al.Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol Psychiatry. 2011;70(1):97–105. https://doi.org/10.1016/j.biopsych.2011.02.011.
27. Van der Kemp WJ, Klomp DW, Kahn RS, Luijten PR, Hulshoff HE. A metaanalysis
of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophr Res. 2012;141(2-3):153–61. https://doi.org/10.1016/j.schres.2012.08.014.
28. McEvoy J, Baillie RA, Zhu H, Buckley P, Keshavan MS, Nasrallah HA, et al.Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS ONE. 2013;8(7): e68717. https://doi.org/10.1371/journal.pone.0068717.
29. McNamara RK. Deciphering the role of docosahexaenoic acid in brain maturation and pathology with magnetic resonance imaging. Prostagl Leukot Essent Fat Acids. 2013;88(1):33–42. https://doi.org/10.1016/j.plefa.2012.03.011.
30. Rice SM, Schafer MR, Klier C, Mossaheb N, Vijayakumar N, Amminger GP. Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controls. Psychiatry Res.2015;228(1):174–6. https://doi.org/10.1016 /j. psychres .2015.04.036.
31. Hoen WP, Lijmer JG, Duran M, Wanders RJ, van Beveren NJ, de Haan L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res. 2013;207(1-2):1–12. https://doi.org/10.1016/j.psychres.2012.09.041.
32. McNamara RK, Jandacek R, Rider T, Tso P, Cole-Strauss A, Lipton JW. Differential effects of antipsychotic medications on polyunsaturated fatty acid biosynthesis in rats: relationship with liver delta 6-desaturaseexpression. Schizophr Res. 2011;129(1):57–65.
33. McNamara RK, Jandacek R, Rider T, Tso P, Hahn CG, Richtand NM, et al. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: Gender differences and partial normalization with antipsychotic medications. Schizophr Res. 2007;91(1-3):37–50. https://doi.org/10.1016/j.schres.2006.11.027.
34. Miller J, Drost DJ, Jensen E, Manchanda R, Northcott S, Neufeld RW, et al.Progressive membrane phospholipid changes in first episode schizophrenia with high field magnetic resonance spectroscopy. Psychiatry Res. 2012;201(1):25–33. https://doi.org/10.1016 /j. pscychresns.2011.06.017.
35. Taha AY, Cheon Y, Ma K, Rapoport SI, Rao JS. Altered fatty acid concentrations in prefrontal cortex of schizophrenic patients. J Psychiatr Res. 2013;47(5):636–43. https:// doi.org/10.1016/j.jpsychires.2013.01.016.
36. Hamazaki K, Hamazaki T, Inadera H. Fatty acid composition in the postmortem amygdala of patients with schizophrenia, bipolar disorder, and major depressive disorder. J Psychiatr Res. 2012;46(8):1024–8. https://doi.org/10.1016/j.jpsychires.2012.04.012.
37. Hamazaki K, Maekawa M, Toyota T, Dean B, Hamazaki T, Yoshikawa T. Fatty acid composition of the postmortem prefrontal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder. Psychiatry Res. 2015;227(2-3):353–9. https://doi.org /10.1016 /j. psychres.2015.01.004.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Farhat Ameer Chughtai
Senior Demonstrator, Department of Pharmacology, Nishtar Medical University, Multan
Muhammad Masood Ahmed
Associate Professor, Pharmacology, Pharmacy College, Nishtar Medical University, Multan.
Saif Ur Rehman
Senior Demonstrator, CMH Multan, Institute of Medical Sciences, Multan (PMDC reg#21455-P).
Abdul Qadir Khan
Program Director, Pharmacy College, Nishtar Medical University, Multan.
Khawar Ali
Department of Molecular Biology Virtual University of Pakistan.
Ghulam Murtaza
Department of Molecular Biology University of Okara Pakistan.
Khawar Ghaffar
Quaid e Azam Medical College Bahawalpur.